Skip to main content
Shenzhen Chipscreen Biosciences Co., Ltd. logo

Shenzhen Chipscreen Biosciences Co., Ltd. — Investor Relations & Filings

Ticker · 688321 ISIN · CNE100003LW0 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 967 across all filing types
Latest filing 2023-04-21 Annual Report
Country CN China
Listing Shanghai Stock Exchange 688321

About Shenzhen Chipscreen Biosciences Co., Ltd.

https://www.chipscreen.com/en/

Shenzhen Chipscreen Biosciences Co., Ltd. specializes in the discovery and development of original small molecule innovative drugs. The company leverages its proprietary chemical genomics-based drug discovery and early evaluation platform to address unmet medical needs in oncology, metabolic diseases, and autoimmune disorders. Its portfolio includes Chidamide (Epidaza), a selective histone deacetylase (HDAC) inhibitor approved for peripheral T-cell lymphoma and advanced breast cancer, and Chiglitazar (Bilessyl), a novel PPAR pan-agonist for type 2 diabetes. Chipscreen Biosciences maintains an integrated R&D system covering drug discovery, clinical development, and commercialization, focusing on molecular mechanisms and translational medicine to provide novel therapeutic solutions.

Recent filings

Filing Released Lang Actions
深圳微芯生物科技股份有限公司2022年度报告
Annual Report Classification · 100% confidence The document is titled "2022 年年度报告" which translates to "2022 Annual Report." It is issued by Shenzhen Chipscreen Biosciences Co., Ltd. The content includes a letter to shareholders, company overview, financial data, management discussion and analysis, audit report mention by KPMG, and detailed financial statements. The document length is 15,000 characters, indicating a comprehensive report rather than a brief announcement. It contains actual financial data, management analysis, and audit opinions, which are typical components of an Annual Report (10-K equivalent). Therefore, this document is classified as an Annual Report (10-K). FY 2022
2023-04-21 Chinese
第二届监事会第十七次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Shenzhen Microchip Biotechnology Co., Ltd. It details the approval of various reports and proposals related to the company's 2022 fiscal year, including the 2022 Supervisory Board Work Report, 2022 Financial Final Accounts Report, 2023 Financial Budget Report, 2022 Profit Distribution Plan, 2022 Internal Control Evaluation Report, 2022 Fundraising Use Report, and the 2022 Annual Report and its summary. However, the document itself does not contain the full annual report or detailed financial statements; instead, it states that these reports will be submitted to the 2022 Annual General Meeting and are available on the Shanghai Stock Exchange website. The document is relatively short (2568 characters) and serves as an official announcement of the Supervisory Board's resolutions and approvals rather than the full reports themselves. According to the "Menu vs Meal" rule, this is an announcement of reports, not the reports themselves. Therefore, the appropriate classification is Regulatory Filings (RNS), as it is a general regulatory announcement that does not fit other specific categories and is not the full annual report.
2023-04-21 Chinese
深圳微芯生物科技股份有限公司2022年内部控制评价报告
Audit Report / Information Classification · 95% confidence The document is titled as an "Internal Control Evaluation Report" for the year 2022 by Shenzhen Microchip Biotechnology Co., Ltd. It discusses the evaluation of the company's internal control effectiveness as of December 31, 2022, including financial reporting internal control and non-financial reporting internal control. The document contains detailed information about the scope, standards, and conclusions of the internal control evaluation, including the absence of major defects and the audit opinion consistency. It is a standalone report focused on internal control evaluation rather than a full annual report or audit report. Given the detailed nature and focus on internal control evaluation, this fits best under the category of Audit Report / Information (AR), which includes standalone audit reports and applied accounting principles, excluding full annual reports. The document length is under 5,000 characters but contains substantive content, so it is not a mere announcement. Therefore, the classification is AR with high confidence. FY 2022
2023-04-21 Chinese
对深圳微芯生物科技股份有限公司募集资金2022年度存放与实际使用情况专项报告的鉴证报告
Audit Report / Information Classification · 100% confidence The document is a detailed auditor's assurance report on the special report regarding the storage and actual use of raised funds by Shenzhen Microchip Biotechnology Co., Ltd. for the year 2022. It references regulatory guidelines from the China Securities Regulatory Commission (CSRC) and the Shanghai Stock Exchange, specifically the "Listed Company Regulatory Guidelines No. 2 - Management and Use of Raised Funds (2022 Revision)". The report includes detailed financial data on the raised funds, their usage, balances, and compliance with regulatory requirements. It is issued by KPMG Huazhen LLP, an accounting firm, providing an assurance opinion on the special report. This type of document is a standalone audit or assurance report on a specific financial aspect (raised funds usage), not a full annual report or interim report. It is not a mere announcement or certification but contains substantive financial data and auditor's opinion. Therefore, it fits the category of Audit Report / Information (AR). FY 2022
2023-04-21 Chinese
监事会关于2022年度利润分配方案的确认意见
Notice of Dividend Amount Classification · 90% confidence The document is a confirmation opinion from the Supervisory Board regarding the 2022 annual profit distribution plan. It references the profit distribution plan for the year 2022 and mentions submission to the shareholders' meeting for approval. The document is very short (508 characters) and mainly consists of a formal opinion and signatures, without detailed financial data or full report content. It does not contain the full annual report or financial statements but is related to dividend or profit distribution announcement. Given the nature of the content and length, it fits best as a Notice of Dividend Amount (DIV) since it concerns profit distribution plans and shareholder interests.
2023-04-21 Chinese
自愿披露关于CS23546片临床试验申请获得受理的公告
Regulatory Filings Classification · 95% confidence The document is a voluntary disclosure announcement by Shenzhen Microchip Biotechnology Co., Ltd. regarding the acceptance of a clinical trial application for a new drug (CS23546). It includes details about the drug, the clinical trial phase, regulatory acceptance by the National Medical Products Administration, and risk warnings for investors. The document is an official announcement about a regulatory acceptance event, not a financial report, earnings release, or management discussion. It does not contain financial data or detailed financial analysis. The document length is short (1177 characters), and it serves as a regulatory announcement about a clinical trial application acceptance. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-04-18 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.